EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Omega Therapeutics's enterprise value is $186.72 Mil.
Omega Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $4.94 Mil. Therefore, Omega Therapeutics's EV-to-Revenue for today is 37.80.
The historical rank and industry rank for Omega Therapeutics's EV-to-Revenue or its related term are showing as below:
OMGA'
s EV-to-Revenue Range Over the Past 10 Years
Min: -166.44 Med: 93.1 Max: 2897.81
Current: 37.8
During the past 5 years, the highest EV-to-Revenue of Omega Therapeutics was 2897.81. The lowest was -166.44. And the median was 93.10.
OMGA's EV-to-Revenue is ranked worse than 74.59% of 1039
companies
in the Biotechnology industry
Industry Median: 8.37
vs OMGA: 37.80
The historical data trend for Omega Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Omega Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Omega Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omega Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Omega Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Omega Therapeutics's EV-to-Revenue falls into.
Omega Therapeutics's current Enterprise Value is $186.72 Mil.
Omega Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omega Therapeutics's share price for today is $1.96.
Omega Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omega Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Omega Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Omega Therapeutics (Omega Therapeutics) Business Description
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. It primarily operates in the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OMGA has been successfully added to your 